Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLITTER

Financiado

Cerrado

Glioblastoma Inhibition Targeting Tumour derived Extracellular Vesicle Driven C...

Glioblastoma Inhibition Targeting Tumour derived Extracellular Vesicle Driven Cell Recruitment Glioblastomas (GBMs) are malignant brain tumours and among the most aggressive human cancers. GBMs patients have an extremely poor survival rate due to a complete absence of adequate therapies capable of efficiently targeting GBM... ver más

31/01/2019

STICHTING AMSTERDA...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2019-01-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

STICHTING AMSTERDAM UMC

0.00€ | Lider

STICHTING VU

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Gl.EXO Innovative tools to detect Glioblastoma GBM exosomes 176K€ Cerrado

GlioDx GlioDx Blood platelet based monitoring and treatment optim... 150K€ Cerrado

OncoViroMRI Brain Cancer Therapy Monitoring using a Novel Quantitative a... 270K€ Cerrado

SAF2011-23870 MEJORA DE LOS PROTOCOLOS PARA DIAGNOSTICO Y SEGUIMIENTO DE R... 327K€ Cerrado

VESSEL CO-COPTION Vessel co option and radioresistance in glioblastoma 1M€ Cerrado

PID2019-110987RB-I00 UNA NUEVA PLATAFORMA DE DIAGNOSTICO DE BIOPSIA LIQUIDA: DETE... 157K€ Cerrado

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Glioblastomas (GBMs) are malignant brain tumours and among the most aggressive human cancers. GBMs patients have an extremely poor survival rate due to a complete absence of adequate therapies capable of efficiently targeting GBM cells inside the brain. Recently, we demonstrated that GBM cells release pro-tumoural extracellular vesicles (EVs) into the bloodstream, which emerged as important intermediates in communication with distant peripheral cells in the body. Of note, the distribution of GBM-derived EVs can now be monitored in vivo by employing a novel Cre/LoxP mouse reporter model. This sophisticated imaging model enables the visualisation of normal peripheral cells that have taken up circulating GBM-derived EVs and allows for subsequent tracking of the recruitment of these cells to the tumour. Recent studies have shown that GBM-derived EVs have the capability to manipulate non-neoplastic cells, exploiting them for tumour expansion. Moreover, we have preliminary evidence that GBM-derived EV receptor pathways can be identified and blocked, possibly causing stagnation of GBM tumour growth by preventing recruitment of essential support cells. We aim at identifying these pathways using unbiased RNAi screening, followed by interference with pro-tumoural cell recruitment, using small molecule drugs in our GBM in vivo models. Finally, circulating GBM-derived EVs and their RNA content are also efficiently captured and internalised by blood platelets (PLTs) that can act as efficient EV carriers. Hence, tumour-derived RNA in circulating EVs and PLTs, isolated from the blood of GBM mouse models and patients, may serve as non-invasive biomarkers and companion diagnostics platform. GLITTER aims to; 1) Analyse in detail the EV-driven recruitment and signalling of essential GBM support cells; 2) Halt GBM tumour growth by interference with EV-mediated recruitment of pro-tumoural non-neoplastic cells; 3) Validate the EV/PLT-based diagnostic platform.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores